Pink SheetThe US Food and Drug Administration’s newly revised stand on testosterone labeling for cardiovascular risk is the visible tip of the metaphorical iceberg of years of effort that went into evaluating a
ScripRivus Pharmaceuticals Inc. already had its lead Controlled Metabolic Accelerator (CMA), known as HU6, in a Phase IIa clinical trial last year when it raised $35m in series A venture capital. Now, wit
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie Continues Development Of Novel S
ScripBelow is Scrip’s regular roundup, including information from Strategic Transactions , of recent technology transfer agreements between companies and academic or other research institutions. OncoSec